Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 4/20 | 0.50 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.50 |
| ▸ | KIF11 | P52732 | 7/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.44 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2490410 | 1.00 | SLC6A11 (0.50) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL12199494 | 0.94 | KIF11 (0.51) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL2491594 | 0.93 | SLC6A11 (0.45) | SLC6A11SLC6A1MEN1TP53CYP1A2 | |
| SCHEMBL6040158 | 0.91 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL2385290 | 0.91 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL2400336 | 0.91 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL13575115 | 0.91 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL334143 | 0.90 | SLC6A11 (0.48) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL8860350 | 0.89 | SLC6A11 (0.47) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL6849984 | 0.88 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| EP-3130597-B1 | OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL | KYOWA KIRIN CO LTD (JP) | 2021-11-10 | — | — | EP | disclosed |
| CN-109651396-B | Alkylation of alkyl fluoroalkylsulfonates | 诺华股份有限公司 | 2021-09-14 | — | — | CN | disclosed |
| US-10568822-B2 | Melanogenesis inhibitor comprising d-pantothenyl alcohol, and skin-whitening cosmetic containing same melanogenesis inhibitor | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2020-02-25 | — | — | US | disclosed |
| EP-3010926-B1 | ALKYLATION WITH AN ALKYL FLUOROALKYL SULFONATE | NOVARTIS AG (CH) | 2019-11-20 | — | — | EP | disclosed |
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-07-09 | — | — | US | disclosed |
| EP-2380567-B1 | MELANIN PRODUCTION INHIBITOR | POLA CHEM IND INC (JP) | 2019-01-16 | — | — | EP | disclosed |
| EP-2380567-B1 | MELANIN PRODUCTION INHIBITOR | POLA CHEM IND INC (JP) | 2019-01-16 | — | — | EP | disclosed |
| US-10131908-B2 | 5′ phosphate mimics | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| EP-0880532-A4 | NON-NUCLEOTIDE PHOSPHOROUS ESTER OLIGOMERS | PHARMAGENICS INC (US) | 1999-06-09 | — | — | EP | disclosed |
| EP-0880532-A1 | NON-NUCLEOTIDE PHOSPHOROUS ESTER OLIGOMERS | PHARMAGENICS, INC. (US) | 1998-12-02 | — | — | EP | disclosed |
| EP-0804443-A4 | NON-NUCLEOTIDE PHOSPHORUS ESTER OLIGOMERS | PHARMAGENICS INC (US) | 1998-04-29 | — | — | EP | disclosed |
| WO-1998013069-A2 | FLUORINATED COPOLYMERIC PHARMACEUTICAL ADJUNCTS | SUPRATEK PHARMA, INC. (CA) | 1998-04-02 | — | — | WO | disclosed |
| EP-0804443-A1 | NON-NUCLEOTIDE PHOSPHORUS ESTER OLIGOMERS | PHARMAGENICS, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1997028168-A1 | NON-NUCLEOTIDE PHOSPHOROUS ESTER OLIGOMERS | PHARMAGENICS, INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| WO-1996022297-A9 | NON-NUCLEOTIDE PHOSPHORUS ESTER OLIGOMERS | — | 1996-10-03 | — | — | WO | disclosed |
| WO-1996022297-A1 | NON-NUCLEOTIDE PHOSPHORUS ESTER OLIGOMERS | PHARMAGENICS, INC. (US) | 1996-07-25 | — | — | WO | disclosed |
| EP-0552185-A1 | SYNTHESIS OF OLIGONUCLEOTIDES | ZENECA LIMITED (GB) | 1993-07-28 | — | — | EP | disclosed |
| WO-1992006103-A1 | SYNTHESIS OF OLIGONUCLEOTIDES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342819-B2 | Oligonucleotide having non-natural nucleotide at 5′-terminal thereof | RNGTT, UPF1, NSUN3 | SLC6A11 4665/4885SLC6A1 4581/4885KIF11 3637/4885 |
| US-10131908-B2 | 5′ phosphate mimics | NSUN2, RNGTT, RNMT | SLC6A11 4504/4885SLC6A1 4105/4885KIF11 4094/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | SLC6A11 1634/4885SLC6A1 1210/4885KIF11 2633/4885 |
| US-10568822-B2 | Melanogenesis inhibitor comprising d-pantothenyl alcohol, and skin-whitening cosmetic containing same melanogenesis inhibitor | MC1R, TYR, NAMPT | SLC6A11 2306/4885SLC6A1 2593/4885KIF11 3669/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | SLC6A11 1634/4885SLC6A1 1210/4885KIF11 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.